The newly published trial tested Lilly's retatrutide in adults with obesity who don't have diabetes. Dr O'Connor calls it another big step for next generation obesity drugs.
Recap by typeshit. Post by @drthomasoconnor on Instagram.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
A Facebook explainer says that as of October 2026 retatrutide remains an investigational drug, not cleared by the FDA for any indication.
Feller urges people on GLP-1s to work with a registered dietitian and their provider so they keep getting enough nutrients while losing weight.
Loading…